This article was originally published in The Gray Sheet
Edwards will focus development of peripheral drug-eluting stents on "vessels where we think we can excel," CEO Michael Mussallem reports during Feb. 3 earnings call. "For example, we think we can do quite well in the SFA," or superficial femoral artery, he says. Edwards has several internal peripheral DES programs, including a research alliance with San Diego-based Happy Valley Medical, developer of the anti-proliferative drug Ceracor (C6-ceramide). HVM is also the "sister company" of stent developer Reva Medical. Meanwhile, Boston Scientific and J&J/Cordis will soon turn their attention to renal drug-eluting stents, Mussallem predicts. "The first target [for] the coronary players...will be the renals. That's a natural target for interventional cardiologists and a natural place for them to be effective"...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.